Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of ACE-031 and IGF-1 (Insulin-like Growth Factor 1) — mechanism, dosing, side effects, legal status, and pricing.
ACE-031 (ramatercept) is a soluble fusion protein of the activin receptor IIB (ActRIIB) extracellular domain and human IgG1 Fc, developed by Acceleron Pharma as a myostatin/activin ligand trap for muscle-wasting disorders. Clinical development was HALTED in 2011 after unexpected vascular adverse events (epistaxis, telangiectasia) attributed to off-target BMP-9/10 inhibition. NOT FDA-approved; all further development was terminated. Now sold only as a grey-market research chemical. WADA-prohibited (myostatin inhibitor).
Insulin-like Growth Factor 1, a 70-amino-acid peptide hormone that mediates many of growth hormone's anabolic effects. Recombinant IGF-1 (mecasermin) is FDA-approved for severe primary IGF-1 deficiency; non-prescription 'research' use for muscle growth is off-label and unproven.
ACE-031
IGF-1 (Insulin-like Growth Factor 1)
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
ACE-031
1 vendor lists this, but none clear the trust bar (score ≥70) yet.
Check ACE-031 prices →IGF-1 (Insulin-like Growth Factor 1)
No pricing data yet.
Check IGF-1 (Insulin-like Growth Factor 1) prices →COA corpus from Disclosed Labs — independently tested batches only.
ACE-031
1
COAs
99.8%
Avg purity
1
Labs
IGF-1 (Insulin-like Growth Factor 1)
1
COAs
—
Avg purity
1
Labs
Phase 2 in ambulatory boys with Duchenne muscular dystrophy was terminated early in 2011 after unexpected nose-bleeds and telangiectasia were observed (attributed to off-target BMP-9/10 neutralization); published results later showed no significant 6MWT benefit vs. placebo in the truncated trial (Campbell et al., Muscle & Nerve, 2017; PMID 27462804). A single-ascending-dose Phase 1 study in healthy postmenopausal women (Attie et al., Muscle & Nerve, 2013; PMID 23169607) showed dose-dependent modest lean-mass increase but also the same vascular signal. Acceleron formally discontinued ACE-031 in 2013 and pivoted to other ActRII programs. No FDA approval; development TERMINATED for vascular safety. WADA-prohibited.
Strong endocrinology literature for deficiency states; performance/anti-aging use in healthy adults is not supported by controlled human trials and carries growth-signaling risk.
ACE-031 and IGF-1 (Insulin-like Growth Factor 1) are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Side Effects
Contraindications
Lab Testing
Disclosed Labs